Skip to main content
Contact Us
Subscribe
E-Edition
54°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
6.050
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
October 07, 2024
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential.
Via
Benzinga
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
September 26, 2024
New study suggests psilocybin may help treat body dysmorphic disorder by rewiring brain connectivity and reducing obsessive thought patterns.
Via
Benzinga
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
September 15, 2024
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.
Via
Talk Markets
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
September 12, 2024
Via
Benzinga
Exposures
Product Safety
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
September 10, 2024
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...
Via
Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
September 06, 2024
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a...
Via
Talk Markets
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
September 05, 2024
Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy.
Via
Benzinga
Exposures
Product Safety
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
August 26, 2024
Via
Benzinga
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
August 24, 2024
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past...
Via
Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
August 15, 2024
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...
Via
Talk Markets
Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript
August 01, 2024
CMPS earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
July 31, 2024
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
Via
Benzinga
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
3 Dirt-Cheap Drug Developers With Blockbuster Potential
July 11, 2024
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
Via
InvestorPlace
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
July 08, 2024
These psychedelic drug stocks aren't as radical as once thought as institutional awareness and emphasize on their potential increases.
Via
InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
July 02, 2024
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns.
Via
InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
Should You Buy the Dip on Compass Pathways Stock?
June 12, 2024
Nothing is going wrong, but one of its peers just hit a serious snag.
Via
The Motley Fool
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.
June 10, 2024
Regulators were not impressed by one company's petition for approval.
Via
The Motley Fool
Exposures
Product Safety
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
June 09, 2024
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.
Via
Talk Markets
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 05, 2024
Via
Benzinga
What's Going On With MindMed And Psychedelic Stocks?
June 05, 2024
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD)....
Via
Benzinga
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
June 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 05, 2024
Via
Benzinga
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
June 05, 2024
Via
Benzinga
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 03, 2024
Via
Benzinga
These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring
May 21, 2024
Psychedelic medicines are rapidly gaining legitimacy on several fronts.
Via
The Motley Fool
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
May 09, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript
May 09, 2024
CMPS earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.